2-morpholino-5-methoxy-4,6-dichloropyrimidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-morpholino-5-methoxy-4,6-dichloropyrimidine
• 英文别名: 2-Morpholino-5-methoxy-4,6-dichloro-pyrimidine；4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine
• 化学式: C₉H₁₁Cl₂N₃O₂
• 分子量: 264.111
• InChiKey: DXHADVLGURXNED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  47.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-morpholino-5-methoxy-4,6-dichloropyrimidine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 32.0h， 生成 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-3-ol
  参考文献：
  名称：

  [EN] PYRIMIDINES AND METHODS OF THEIR USE
  [FR] PYRIMIDINES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Disclosed are compounds comprising pyrimidinyl core and pharmaceutical compositions useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases, including FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.

  公开号：

  WO2023107603A1
• 作为产物：
  描述：

  5-methoxy-2-morpholinopyrimidine-4,6-diol 在 三氯氧磷 作用下， 以51.6 %的产率得到2-morpholino-5-methoxy-4,6-dichloropyrimidine
  参考文献：
  名称：

  [EN] PYRIMIDINES AND METHODS OF THEIR USE
  [FR] PYRIMIDINES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Disclosed are compounds comprising pyrimidinyl core and pharmaceutical compositions useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases, including FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.

  公开号：

  WO2023107603A1

文献信息

• Pyrimidines
  申请人：Societe Generale de Recherches et d'Applications Scientifiques "Sogeras"

  公开号：US03984411A1

  公开（公告）日：1976-10-05

  Compounds having the formula ##SPC1## Process for the preparation of such compounds which comprises reacting a pound having the formula: ##SPC2## Medicaments containing a compound of formula (I) or a salt thereof with a pharmaceutically acceptable acid; compounds of formula: ##SPC3## Wherein R represents alkyl or alkoxy having 1 to 4 carbon atoms, benzyl, p-chlorophenyl or p-chlorophenoxy and compounds of formula: ##SPC4## Wherein R represents alkoxy having 2 to 4 carbon atoms, p-chlorophenyl or p-chlorophenoxy.

  具有化学式##SPC1##的化合物。制备这些化合物的方法包括反应具有以下化学式的化合物：##SPC2##含有化学式(I)的化合物或其与药用酸盐；化学式：##SPC3##其中R代表1至4个碳原子的烷基或烷氧基，苄基，对氯苯基或对氯苯氧基；化学式：##SPC4##其中R代表2至4个碳原子的烷氧基，对氯苯基或对氯苯氧基。
• US3984411A
  申请人：——

  公开号：US3984411A

  公开（公告）日：1976-10-05
• [EN] PYRIMIDINES AND METHODS OF THEIR USE<br/>[FR] PYRIMIDINES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]KINETA, INC.

  公开号：WO2023107603A1

  公开（公告）日：2023-06-15

  Disclosed are compounds comprising pyrimidinyl core and pharmaceutical compositions useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases, including FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.